EGFR and lung adenocarcinoma: demonstrated that SIRT5 drives immune evasion in EGFR-mutant lung adenocarcinomas by desuccinylating ACAT1, activating NRF2, and suppressing the release of chemokines essential for CD8+ T cell recruitment (161).